Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

Gregory G. Schwartz, Michael Szarek, Vera A. Bittner, Rafael Diaz, Shaun G. Goodman, J. Wouter Jukema, Ulf Landmesser, Patricio López-Jaramillo, Garen Manvelian, Robert Pordy, Michel Scemama, Peter Sinnaeve, Harvey D. White, Ph Gabriel Steg, ODYSSEY OUTCOMES Committees and Investigators, Philip E. Aylward, Sam J. Lehman

Research output: Contribution to journalArticlepeer-review

65 Citations (Scopus)
72 Downloads (Pure)

Fingerprint

Dive into the research topics of 'Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science